Watch List for Traders: Baidu (NASDAQ:BIDU), American Residential Properties (NYSE:ARPI), Arena Pharmaceuticals (NASDAQ:ARNA), AbbVie Inc. (NYSE:ABBV), Avon Products Inc. (NYSE:AVP)


Baidu Inc (ADR) (NASDAQ:BIDU) shares moved down -3.21% in last trading session and ended the day at $147.25. BIDU Gross Margin is 60.70% and its has a return on assets of 12.60%. Baidu Inc (ADR) (NASDAQ:BIDU) quarterly performance is -27.59%.

Baidu Inc (ADR) (NASDAQ:BIDU) is a Chinese-language Internet search provider (ISP). Baidu serves three types of online participants, which include users, customers and Baidu Union Members. The Company offers a Chinese-language search platform on its Website, Baidu.com. It provides Chinese-language Internet search services to enable users to find relevant information online, including Web pages, news, images, documents and multimedia files, through links provided on its Websites.

It was reported on 27 August, that Baidu Inc (ADR) (NASDAQ:BIDU) is taking it on the chin due to economic events in China and its decision to spend more on sales and marketing for its online-to-offline business. This Zacks Rank #5 (Strong Sell) is expected to see falling earnings this year.

American Residential Properties, Inc. (NYSE:ARPI) ended the last trading day at $16.95. Company weekly volatility is calculated as 3.44% and price to cash ratio as 26.01. American Residential Properties, Inc. (NYSE:ARPI) showed a weekly performance of 3.61%.

American Residential Properties, Inc. (NYSE:ARPI) is an internally managed real estate investment company, which is organized as a real estate investment trust. The Company acquires, owns, renovates, and manages single-family homes as rental properties. American Residential Properties OP, L.P. acts as its operating partnership. American Residential Leasing Company, LLC is a wholly owned subsidiary of its operating partnership.

American Residential Properties, Inc. (NYSE:ARPI) announced on 27 August, that it will participate in upcoming investor conferences and an industry event. Co-Founders Stephen Schmitz, Chairman and Chief Executive Officer, and Laurie Hawkes, President and Chief Operating Officer, will attend the Zelman & Associates 2015 Housing Summit on September 10-11, 2015 at the Mandarin Oriental in Washington, D.C. Schmitz will participate in the “Single-Family Rental Panel” at 9:45 a.m. ET on Friday, September 11. The presentation will not be webcast.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) caters to the Healthcare space. Its weekly performance is -0.18%. On the last day of trading company shares ended up $2.71. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) distance from 50-day simple moving average (SMA50) is -30.68%.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors (GPCRs). The Company’s drug, BELVIQ (lorcaserin HCl), was approved by the United States Food and Drug Administration for marketing in the United States. In addition to BELVIQ, the Company has other drug candidates and compounds at various stages of research and development.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) on August 27, 2015,reportedArena Solutions, the pioneer of cloud-based product lifecycle management (PLM) applications, declared that its flagship product, Arena PLM, now integrates with Kenandy Cloud ERP, an enterprise resource planning system for midmarket and large global enterprises built on the Salesforce Platform. With this integration, the product record can be automatically passed from Arena PLM to Kenandy at the point of change approval.

AbbVie Inc. (NYSE:ABBV) shares decreased -2.45% in last trading session and ended the day at $62.41. ABBV Gross Margin is 80.70% and its has a return on assets of 6.10%. AbbVie Inc. (NYSE:ABBV) quarterly performance is -5.62%.

AbbVie Inc. (NYSE:ABBV) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone.

AbbVie Inc. (NYSE:ABBV) has bought a priority review voucher from United Therapeutics Corp for $350 million that will allow it to accelerate the review process for one of its drugs. United Therapeutics received a rare pediatric disease priority review voucher in March after its drug, Unituxin, was approved by the U.S. Food and Drug Administration to treat neuroblastoma, the company said on 19 August.

Avon Products Inc. (NYSE:AVP) caters to the Consumer Goods space. It has a net profit margin of -4.40% and weekly performance is 18.49%. On the last day of trading company shares ended up $5.19. Avon Products Inc. (NYSE:AVP) distance from 50-day simple moving average (SMA50) is -10.08%.

Avon Products, Inc. (NYSE:AVP) is a manufacturer and marketer of beauty and related products. The Company’s offers its products under two product categories: Beauty and Fashion & Home. Beauty consists of skincare (which includes personal care), fragrance and color (cosmetics). Fashion & Home consists of fashion jewelry, watches, apparel, footwear, accessories, gift and decorative products, housewares, entertainment and leisure products, children’s products and nutritional products.

It was reported on 20 August, that Avon Products Inc. (NYSE:AVP) is seeking authorization of a $62 million settlement of a U.S. lawsuit accusing the cosmetics firm of defrauding shareholders by concealing its failure to stop workers from bribing officials in China to win business according to Reuters. The proposed settlement was filed on Tuesday with the U.S. District Court in Manhattan and requires a judge’s authorization. It resolves claims that Avon, former Chief Executive Andrea Jung and former Chief Financial Strategy Officer Charles Cramb, intended to mislead shareholders from 2006 to 2011 about the company’s ability to comply with the federal Foreign Corrupt Practices Act, which prohibits bribing foreign officials.


Leave a Reply

Your email address will not be published. Required fields are marked *